Amylyx Pharmaceuticals (AMLX) Stock Forecast & Price Target

Amylyx Pharmaceuticals is viewed favorably because avexitide delivered a highly convincing Phase 3 LUCIDITY result in PBH, cutting Level 2 and Level 3 hypoglycemic events by 55% versus placebo with all secondary endpoints met and clean safety, which materially strengthens the probability of approval and the credibility of the program. The company’s positioning in a rare disease with no approved alternative supports premium pricing, broad reimbursement, and regulatory flexibility, while an identified treatment-ready patient base, Expanded Access Program, and “Uncover PBH” education campaign should help accelerate adoption. The broader pipeline in Wolfram Syndrome, ALS, and post-bariatric hypoglycemia-related follow-on assets adds durability, and the cited estimates point to a fully diluted market cap of $8.2B, $3.5B avexitide sales in 2035E, and a path to profitability.

Amylyx Pharmaceuticals is facing a fundamentally fragile investment case because its value depends heavily on a small number of clinical-stage assets, with avexitide and AMX0035 carrying the bulk of the commercial and regulatory upside. The stated risks—especially Phase 3 efficacy or safety shortfalls in adults with PBH, delays in R&D or regulatory progress, and competition in the PBH space—could quickly erode confidence in the pipeline before meaningful revenue is established. Even though the valuation framework assumes a 20x multiple of 2034 EPS of $7.30 and an NPV of $50/share, those estimates rest on successful clinical data, approvals in the US and EU, and peak revenue assumptions that may prove too optimistic.